Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orticumab in Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
NCT04776629Phase 2Completed
- Sponsor
- Abcentra
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of orticumab in psoriasis, sponsored by Abcentra. Started Jun 2021; status: completed.
02
Drugs
orticumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT04776629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776629.